These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38133623)

  • 1. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
    Verma S; Pandey A; Pandey AK; Butler J; Lee JS; Teoh H; Mazer CD; Kosiborod MN; Cosentino F; Anker SD; Connelly KA; Bhatt DL
    Am J Physiol Heart Circ Physiol; 2024 Mar; 326(3):H670-H688. PubMed ID: 38133623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone Stimulates Its Biosynthesis Via a Novel GPER-Mediated Mechanism.
    Caroccia B; Seccia TM; Piazza M; Prisco S; Zanin S; Iacobone M; Lenzini L; Pallafacchina G; Domening O; Poglitsch M; Rizzuto R; Rossi GP
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6316-6324. PubMed ID: 31125081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
    Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
    Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects.
    Freel EM; Ingram M; Wallace AM; White A; Fraser R; Davies E; Connell JM
    Clin Endocrinol (Oxf); 2008 May; 68(5):700-6. PubMed ID: 17980006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
    Unger T; Paulis L; Sica DA
    Eur Heart J; 2011 Nov; 32(22):2739-47. PubMed ID: 21951628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human.
    Cerny MA; Csengery A; Schmenk J; Frederick K
    J Steroid Biochem Mol Biol; 2015 Nov; 154():197-205. PubMed ID: 26303746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone synthase inhibitors in cardiovascular and renal diseases.
    Namsolleck P; Unger T
    Nephrol Dial Transplant; 2014 Feb; 29 Suppl 1():i62-i68. PubMed ID: 24493871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into aldosterone synthase substrate specificity and targeted inhibition.
    Strushkevich N; Gilep AA; Shen L; Arrowsmith CH; Edwards AM; Usanov SA; Park HW
    Mol Endocrinol; 2013 Feb; 27(2):315-24. PubMed ID: 23322723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of aldosterone synthase: Does this offer advantages compared with the blockade of mineralocorticoid receptors?
    Ando H
    Hypertens Res; 2023 Apr; 46(4):1056-1057. PubMed ID: 36653520
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac aldosterone production in genetically hypertensive rats.
    Takeda Y; Yoneda T; Demura M; Miyamori I; Mabuchi H
    Hypertension; 2000 Oct; 36(4):495-500. PubMed ID: 11040225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.
    Brown NJ
    Nat Rev Nephrol; 2013 Aug; 9(8):459-69. PubMed ID: 23774812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury.
    Tsuji H; Wang W; Sunil J; Shimizu N; Yoshimura K; Uemura H; Peck AB; Khan SR
    World J Urol; 2016 Jan; 34(1):89-95. PubMed ID: 25981400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of a whole-cell based medium throughput screening system for the discovery of human aldosterone synthase (CYP11B2) inhibitors: old drugs disclose new applications for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Hakki T; Hübel K; Waldmann H; Bernhardt R
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):120-8. PubMed ID: 21193036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baxdrostat: A Novel Aldosterone Synthase Inhibitor for Treatment Resistant Hypertension.
    Dogra S; Shah S; Gitzel L; Pusukur B; Sood A; Vyas AV; Gupta R
    Curr Probl Cardiol; 2023 Nov; 48(11):101918. PubMed ID: 37399857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
    Peter M; Dubuis JM; Sippell WG
    Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of Aldosterone Synthase.
    Weldon SM; Brown NF
    Vitam Horm; 2019; 109():211-239. PubMed ID: 30678857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.